Late-breaking clinical trial data demonstrate high rates of primary patency and significantly lower rates of clinically-driven target lesion revascularization for peripheral drug-eluting device portfolio LAS VEGAS and MARLBOROUGH, Mass., Nov. 5, 2019 /PRNewswire/ — Today, Boston Scientific (NYSE: BSX) announced positive data for two devices […]